查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2049131

醫院感染檢測市場報告：按適應症和地區分類（2026-2034 年）

Hospital Acquired Disease Testing Market Report by Indication (UTI (Urinary Tract Infection), SSI (Surgical Site Infection), Pneumonia, Bloodstream Infections, MRSA (Methicillin-Resistant Staphylococcus Aureus), and Others), and Region 2026-2034
出版日期: | 出版商: IMARC | 英文 135 Pages | 商品交期: 2-3個工作天內

價格

2025年，全球醫院感染檢測市場規模達162億美元。展望未來，IMARC Group預測，到2034年，該市場規模將達到536億美元，2026年至2034年的複合年成長率（CAGR）為13.82%。推動該市場成長的因素有很多，包括老年人口的成長、院內感染（HAI）如尿道感染（UTI）、血流感染疾病和肺炎等疾病的盛行率上升，以及接受各種外科手術的人數不斷增加。

院內感染（HAI），也稱為院內感染疾病，是指在醫院或診所內感染的疾病。 「醫院獲得性」意味著感染疾病或疾病起源於醫院環境。此類疾病也可能發生在療養院、復健中心、醫院或其他醫療機構。在許多情況下，HAI發生在住院期間，例如在加護病房（ICU）或急診室（ER）。通常，這些疾病的潛伏期為入院後48小時至4天。 HAI的主要原因之一是醫院工作人員缺乏適當的衛生管理。其他原因包括設施管理不善、醫院工作人員疏忽大意以及多重抗藥性細菌（MDRO）的增加。最常見的HAI包括肺炎、原發性血流感染疾病和尿道感染。在許多情況下，這些HAI被發現與患者本身的微生物群有關。當皮膚的保護層接觸到潛在威脅時，尤其是在手術後，就會發生這種情況，導致感染。

市場趨勢

受人口成長和醫療基礎設施現代化的推動，全球醫療機構數量顯著增加。由此導致醫院感染（HAI）發生率上升，進而推動了對HAI檢測的需求。此外，先進技術和科學創新使得市場上湧現多種用於HAI預防、診斷和監測的技術，包括微陣列、聚合酵素鏈鎖反應（PCR）、即時定位系統（RTLS）和固雜合反應。 RTLS等技術有助於預防HAI在病人和醫護人員之間的傳播。患者對HAI的認知不斷提高，以及政府對HAI發生率高的醫院實施處罰等法規，也是推動市場成長的因素。

市場區隔

本報告分析了各細分市場的關鍵趨勢，並對2026年至2034年進行了全球和區域預測。市場按適應症細分。

按應用細分

  • 尿道感染（UTI）
  • 手術部位感染 (SSI)
  • 肺炎
  • 血液感染疾病
  • 抗藥性金黃色葡萄球菌（MRSA）
  • 其他

根據適應症，市場細分為尿道感染、手術部位感染疾病、肺炎、血流感染疾病、抗藥性金黃色葡萄球菌和其他感染。目前，尿道感染佔據最大的市場。

區域趨勢

  • 北美洲
  • 歐洲
  • 亞太地區
  • 中東和非洲
  • 拉丁美洲

按地區分類，市場分為北美、歐洲、亞太、中東和非洲以及拉丁美洲。

競爭格局

也調查了競爭格局，確定的主要公司包括 Abbott Laboratories、Area、Becton Dickinson & Company、BioMérieux、F. Hoffmann-La Roche、Hologic、QIAGEN、Siemens Health Care、Diatelyx Laboratories、Meridian Biosciences、Thermo Fisher Scientific (Life Technologies) 和 Ceidian Biosciences、Thermo Fisher Scientific (Life Technologies) 和 Ceidian Biosciences、Thermo Fisher Scientific (Life Technologies) 和 Ceidian Biosciences、Thermo Fisher Scientific (Life Technologies)。

本報告深入剖析了全球醫院感染檢測市場的各個關鍵面向。報告涵蓋了廣泛的主題，從宏觀的市場概覽到微觀層面的細節，例如行業表現、近期趨勢、主要市場促進因素和挑戰、SWOT分析、波特五力分析以及價值鏈分析。對於企業家、投資者、研究人員、顧問、商務策略以及所有對醫院感染檢測市場感興趣或計劃進入該市場的人士而言，本報告都是必讀之作。

本報告解答的主要問題

1. 2025年全球醫院感染檢測市場的市場規模為何？

2. 2026 年至 2034 年全球醫院感染檢測市場的預期成長率為何？

3. 全球醫院感染檢測市場的促進因素為何？

4. 全球醫院感染檢測市場的主要產業趨勢為何？

5. COVID-19 對全球醫院感染檢測市場產生了哪些影響？

6. 全球醫院感染檢測市場依適應症分類的情況如何？

7. 全球醫院感染檢測市場的主要區域有哪些？

8. 全球醫院感染檢測市場的主要公司和參與者有哪些？

目錄

第1章：序言

第2章：調查方法

  • 調查目的
  • 相關利益者
  • 數據來源
    • 主要訊息
    • 二手資訊
  • 市場估值
    • 自下而上的方法
    • 自上而下的方法
  • 預測方法

第3章執行摘要

第4章：引言

第5章：全球醫院感染檢測市場

  • 市場概覽
  • 市場表現
  • 新冠疫情的影響
  • 市場區隔：依指標
  • 市場區隔：按地區
  • 市場預測
  • SWOT分析
  • 價值鏈分析
  • 波特五力分析
  • 價格分析

第6章 市場區隔：依適應症分類

  • 尿道感染（UTI）
  • 手術部位感染 (SSI)
  • 肺炎
  • 血液感染疾病
  • 抗藥性金黃色葡萄球菌（MRSA）
  • 其他

第7章 市場區隔：依地區分類

  • 北美洲
  • 歐洲
  • 亞太地區
  • 中東和非洲
  • 拉丁美洲

第8章 競爭情勢

  • 市場結構
  • 大公司
  • 主要公司簡介
    • Abbott Laboratories
    • Alere, Inc.
    • Becton, Dickinson and Company
    • bioMerieux SA
    • F. Hoffmann-La Roche Ltd.
    • Hologic, Inc.
    • QIAGEN
    • Siemens Healthcare
    • Diatherix Laboratories, Inc.
    • Meridian Bioscience, Inc.
    • Thermo Fisher Scientific, Inc.（Life Technologies Corporation）
    • Cepheid, Inc.
Product Code: SR112026A1128

The global hospital acquired disease testing market size reached USD 16.2 Billion in 2025. Looking forward, IMARC Group expects the market to reach USD 53.6 Billion by 2034, exhibiting a growth rate (CAGR) of 13.82% during 2026-2034. There are several factors that are driving the market, which include the rising geriatric population, increasing prevalence of hospital acquired infections (HAIs) like urinary tract infections (UTIs), bloodstream infections, and pneumonia, and the growing number of people undergoing different surgical procedures.

Hospital-acquired infections (HAIs) or nosocomial infections are diseases that are acquired in hospitals and medical clinics. Nosocomial means, infections or diseases originating in a hospital. A person can get such diseases even in the vicinity of a nursing home, rehabilitation center, hospital or any other clinical surroundings. Most people get HAIs when they are in intensive care units (ICUs) and emergency rooms (ERs). Generally, the incubation period of these diseases vary between 48 hours to 4 days after the individual gets admitted. A major reason behind the cause of hospital-acquired diseases is the lack of proper hygiene in the hospital settings by the internal staff. Other reasons can be below-par maintenance, complacency by the hospital staff, and a rise in multi-drug resistant organisms (MDROs). Some of the most commonly occurring nosocomial infections include pneumonia, primary bloodstream infections, urinary tract infections, etc. In many cases, it has also been found that these nosocomial infections are sometimes traced to the patient's own microbiome. It happens when the protective skin layer comes in contact with possible threats and causes infection to occur, especially after surgical operations.

Market Trends

Catalyzed by rising population and modernization of the healthcare infrastructure, there has been a significant increase in the number of health care facilities across the globe. This has resulted in a rising incidence of HAIs, driving the demand of hospital acquired disease tests. Moreover, with advanced technologies and scientific innovations, various techniques are now available in the market for preventing, diagnosing, and monitoring HAIs such as microarrays, polymerase chain reaction (PCR), real time location systems (RTLSs), and solid phase hybridization. Techniques such as RTLS makes it easy to prevent HAIs from spreading in both patients and staff. Growing awareness of HAIs among patients and governments enacting regulations that penalize hospitals having a high incidence of HAIs are some of the other factors that are catalyzing the growth of the market.

Market Segmentation

This report provides an analysis of the key trends in each segment of the market, along with forecasts at the global and regional for 2026-2034. The report has categorized the market based on indication.

Breakup by Indication

  • UTI (Urinary Tract Infection)
  • SSI (Surgical Site Infection)
  • Pneumonia
  • Bloodstream Infections
  • MRSA (Methicillin-Resistant Staphylococcus Aureus)
  • Others

Based on the indication, the market has been segmented into urinary tract infection, surgical site infection, pneumonia, bloodstream infections, methicillin-resistant staphylococcus aureus and others. Urinary tract infection currently represents the biggest segment.

Regional Insights

  • North America
  • Europe
  • Asia Pacific
  • Middle East and Africa
  • Latin America

Region-wise, the market has been segmented into North America, Europe, Asia Pacific, Middle East and Africa, and Latin America.

Competitive Landscape

The competitive landscape of the market has also been examined with some of the key players being Abbott Laboratories, Alere, Inc., Becton, Dickinson and Company, bioMerieux SA, F. Hoffmann-La Roche Ltd., Hologic, Inc., QIAGEN, Siemens Healthcare, Diatherix Laboratories, Inc., Meridian Bioscience, Inc., Thermo Fisher Scientific, Inc. (Life Technologies Corporation) and Cepheid, Inc.

This report provides a deep insight into the global hospital-acquired disease testing market covering all its essential aspects. This ranges from macro overview of the market to micro details of the industry performance, recent trends, key market drivers and challenges, SWOT analysis, Porter's five forces analysis, value chain analysis, etc. This report is a must-read for entrepreneurs, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the hospital-acquired disease testing market in any manner.

Key Questions Answered in This Report

1. What is the market size for the global hospital acquired disease testing market 2025?

2. What is the global hospital acquired disease testing market growth 2026-2034?

3. What are the global hospital acquired disease testing market drivers?

4. What are the key industry trends in the global hospital acquired disease testing market?

5. What is the impact of COVID-19 on the global hospital acquired disease testing market?

6. What is the global hospital acquired disease testing market breakup by indication?

7. What are the major regions in the global hospital acquired disease testing market?

8. Who are the key companies/players in the global hospital acquired disease testing market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Hospital Acquired Disease Testing Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Breakup by Indication
  • 5.5 Market Breakup by Region
  • 5.6 Market Forecast
  • 5.7 SWOT Analysis
    • 5.7.1 Overview
    • 5.7.2 Strengths
    • 5.7.3 Weaknesses
    • 5.7.4 Opportunities
    • 5.7.5 Threats
  • 5.8 Value Chain Analysis
  • 5.9 Porters Five Forces Analysis
    • 5.9.1 Overview
    • 5.9.2 Bargaining Power of Buyers
    • 5.9.3 Bargaining Power of Suppliers
    • 5.9.4 Degree of Competition
    • 5.9.5 Threat of New Entrants
    • 5.9.6 Threat of Substitutes
  • 5.10 Price Analysis

6 Market Breakup by Indication

  • 6.1 UTI (Urinary Tract Infection)
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 SSI (Surgical Site Infection)
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Pneumonia
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 Bloodstream Infections
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast
  • 6.5 MRSA (Methicillin-Resistant Staphylococcus Aureus)
    • 6.5.1 Market Trends
    • 6.5.2 Market Forecast
  • 6.6 Others
    • 6.6.1 Market Trends
    • 6.6.2 Market Forecast

7 Market Breakup by Region

  • 7.1 North America
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Europe
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Asia Pacific
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Middle East and Africa
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast
  • 7.5 Latin America
    • 7.5.1 Market Trends
    • 7.5.2 Market Forecast

8 Competitive Landscape

  • 8.1 Market Structure
  • 8.2 Key Players
  • 8.3 Profiles of Key Players
    • 8.3.1 Abbott Laboratories
    • 8.3.2 Alere, Inc.
    • 8.3.3 Becton, Dickinson and Company
    • 8.3.4 bioMerieux SA
    • 8.3.5 F. Hoffmann-La Roche Ltd.
    • 8.3.6 Hologic, Inc.
    • 8.3.7 QIAGEN
    • 8.3.8 Siemens Healthcare
    • 8.3.9 Diatherix Laboratories, Inc.
    • 8.3.10 Meridian Bioscience, Inc.
    • 8.3.11 Thermo Fisher Scientific, Inc. (Life Technologies Corporation)
    • 8.3.12 Cepheid, Inc.

List of Figures

  • Figure 1: Global: Hospital Acquired Disease Testing Market: Major Drivers and Challenges
  • Figure 2: Global: Hospital Acquired Disease Testing Market: Sales Value (in Billion USD), 2020-2025
  • Figure 3: Global: Hospital Acquired Disease Testing Market: Breakup by Indication (in %), 2025
  • Figure 4: Global: Hospital Acquired Disease Testing Market: Breakup by Region (in %), 2025
  • Figure 5: Global: Hospital Acquired Disease Testing Market Forecast: Sales Value (in Billion USD), 2026-2034
  • Figure 6: Global: Hospital Acquired Disease Testing Industry: SWOT Analysis
  • Figure 7: Global: Hospital Acquired Disease Testing Industry: Value Chain Analysis
  • Figure 8: Global: Hospital Acquired Disease Testing Industry: Porter's Five Forces Analysis
  • Figure 9: Global: Hospital Acquired Disease Testing (Urinary Tract Infection) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 10: Global: Hospital Acquired Disease Testing (Urinary Tract Infection) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 11: Global: Hospital Acquired Disease Testing (Surgical Site Infection) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 12: Global: Hospital Acquired Disease Testing (Surgical Site Infection) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 13: Global: Hospital Acquired Disease Testing (Pneumonia) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 14: Global: Hospital Acquired Disease Testing (Pneumonia) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 15: Global: Hospital Acquired Disease Testing (Bloodstream Infections) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 16: Global: Hospital Acquired Disease Testing (Bloodstream Infections) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 17: Global: Hospital Acquired Disease Testing (Methicillin-Resistant Staphylococcus Aureus) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 18: Global: Hospital Acquired Disease Testing (Methicillin-Resistant Staphylococcus Aureus) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 19: Global: Hospital Acquired Disease Testing (Other Indications) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 20: Global: Hospital Acquired Disease Testing (Other Indications) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 21: North America: Hospital Acquired Disease Testing Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 22: North America: Hospital Acquired Disease Testing Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 23: Europe: Hospital Acquired Disease Testing Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 24: Europe: Hospital Acquired Disease Testing Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 25: Asia Pacific: Hospital Acquired Disease Testing Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 26: Asia Pacific: Hospital Acquired Disease Testing Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 27: Middle East and Africa: Hospital Acquired Disease Testing Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 28: Middle East and Africa: Hospital Acquired Disease Testing Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 29: Latin America: Hospital Acquired Disease Testing Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 30: Latin America: Hospital Acquired Disease Testing Market Forecast: Sales Value (in Million USD), 2026-2034

List of Tables

  • Table 1: Global: Hospital Acquired Disease Testing Market: Key Industry Highlights, 2025 and 2034
  • Table 2: Global: Hospital Acquired Disease Testing Market Forecast: Breakup by Indication (in Million USD), 2026-2034
  • Table 3: Global: Hospital Acquired Disease Testing Market Forecast: Breakup by Region (in Million USD), 2026-2034
  • Table 4: Global: Hospital Acquired Disease Testing Market: Competitive Structure
  • Table 5: Global: Hospital Acquired Disease Testing Market: Key Players